PMID: 8603018Feb 1, 1996Paper

Thrombin-mediated activation of endogenous factor XI in plasma in the presence of physiological glycosaminoglycans occurs only with high concentrations of thrombin

British Journal of Haematology
W A WuilleminC E Hack

Abstract

The variable bleeding tendency associated with a genetic deficiency of factor XI (FXI) and the lack of bleeding disorders in individuals with a genetic deficiency of factor XII (FXII) suggest an alternative mechanism for FXI activation in vivo. Recently, thrombin has been shown to activate FXI. However, in plasma this activation has been shown to occur only with exogenous FXI and a non-physiological cofactor (sulphatides), and the occurrence of this reaction in a plasma environment has been questioned. Using recently developed sensitive assays for FXIa-inhibitor complexes we found thrombin-mediated and FXII-dependent activation of endogenous FXI in plasma in the presence of heparan sulphate, heparin, dermatan sulphate or dextran sulphate. Using heparan sulphate, which is present in the human vascular system, activation of about 1-2% of plasma FXI was observed, however, only after addition of very high amounts (500 nmol/l) of human alpha-thrombin to FXII-deficient plasma (at a 1 to 4 final dilution). We conclude that endogenous FXI in plasma can be activated by thrombin in the presence of various glycosaminoglycans, including the physiological compounds heparan sulphate and dermatan sulphate, but only at very high concentrations...Continue Reading

Citations

Jan 15, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·J A OliverM Hoffman
Jul 19, 2001·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·A Kramoroff, J M Nigretto
May 20, 2017·Scientific Reports·David A DonkorWilliam P Sheffield
Jun 20, 2001·Biochemistry·K O Badellino, P N Walsh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
David Gailani, G J Broze
European Journal of Biochemistry
E A BraatD C Rijken
Arteriosclerosis, Thrombosis, and Vascular Biology
J A OliverM Hoffman
© 2021 Meta ULC. All rights reserved